These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 17049587)

  • 1. PDGFR-alpha as a potential therapeutic target in uterine sarcomas.
    Adams SF; Hickson JA; Hutto JY; Montag AG; Lengyel E; Yamada SD
    Gynecol Oncol; 2007 Mar; 104(3):524-8. PubMed ID: 17049587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP; Matthews KS; Kimball KJ; Conner MG; Baker AC; Barnes MN
    Reprod Sci; 2008 Sep; 15(7):673-7. PubMed ID: 18492696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
    Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas.
    Caudell JJ; Deavers MT; Slomovitz BM; Lu KH; Broaddus RR; Gershenson DM; Ramondetta LM
    Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):167-70. PubMed ID: 15894930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
    Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
    Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
    Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
    Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S; Chen LR; Wang HJ; Chen SZ
    Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis.
    Cossu-Rocca P; Contini M; Uras MG; Muroni MR; Pili F; Carru C; Bosincu L; Massarelli G; Nogales FF; De Miglio MR
    Int J Gynecol Pathol; 2012 Nov; 31(6):570-9. PubMed ID: 23018215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract.
    Rossi G; Valli R; Bertolini F; Marchioni A; Cavazza A; Mucciarini C; Migaldi M; Federico M; Trentini GP; Sgambato A
    Histopathology; 2005 May; 46(5):522-31. PubMed ID: 15842634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series.
    Leath CA; Straughn JM; Conner MG; Barnes MN; Alvarez RD; Partridge EE; Huh WK
    J Reprod Med; 2004 Feb; 49(2):71-5. PubMed ID: 15018431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations.
    Liegl B; Gülly C; Reich O; Nogales FF; Beham A; Regauer S
    Histopathology; 2007 Mar; 50(4):448-52. PubMed ID: 17448020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
    Fjällskog ML; Lejonklou MH; Oberg KE; Eriksson BK; Janson ET
    Clin Cancer Res; 2003 Apr; 9(4):1469-73. PubMed ID: 12684421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.
    Mace J; Sybil Biermann J; Sondak V; McGinn C; Hayes C; Thomas D; Baker L
    Cancer; 2002 Dec; 95(11):2373-9. PubMed ID: 12436445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of c-kit in uterine carcinosarcoma.
    Menczer J; Kravtsov V; Levy T; Berger E; Glezerman M; Avinoach I
    Gynecol Oncol; 2005 Jan; 96(1):210-5. PubMed ID: 15589603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of imatinib mesylate in adjuvant therapy of extra-abdominal desmoid tumors.
    Ioannou M; Demertzis N; Iakovidou I; Kottakis S
    Anticancer Res; 2007; 27(2):1143-7. PubMed ID: 17465254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
    Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
    Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
    Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
    Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.